Following our popular March 2025 Forum, we’re delighted to announce that Hardman & Co, in association with GrowthInvest, will host our second TAS Forum this month.
Are you considering EIS investments for yourself or your clients? We invite you to join the Hardman & Co Tax Advantaged Forum, “New Approaches in EIS”, on 24 September at 12.30pm on Zoom.
You’ll get the chance to hear from some exceptional fund managers, presenting exciting investment opportunities. The event will start with an introduction to EIS/SEIS and an update on current themes, followed by the funds presenting their investment case with a live Q&A.
Why join the webinar?
• Diversification & growth: Discover how to diversify your portfolio by investing in high-growth, early-stage businesses with the potential for high returns.
• Tax relief: EIS offers significant tax advantages that can enhance your portfolio’s performance.
• Expert insights: Hear directly from fund managers showcasing their investment strategy, growth prospects and new opportunities.
Who is speaking?
EverQuest Capital Partners
EverQuest EIS Fund from EverQuest Capital Partners is a venture capital firm backing high-growth and scale-up businesses across the supply chain. It focuses on value-driven sectors with strong near-term exit potential. EverQuest backs disruptive enabling technologies that power the UK industry and invests in Deep MakeTech: advanced processes, materials, and design technologies transforming British manufacturing, with a broad exposure across semiconductors, healthcare, renewables, automotive, agriculture, and defence. The company manages both the EverQuest EIS Fund and the CPI Evergreen Fund. 50% of its portfolio companies tripled in value in the last 12 months, and EverQuest is trusted by co-investors including BGF, Northern Gritstone, and Maven.
Dr Stephane Mery, Partner: Stephane has over 20 years’ experience in private equity and entrepreneurship. He was CEO of BBSF, an early-stage fund behind the success of Spirogen (sold to Astra Zeneca for $400m), and Endomagnetics (sold for $310m to Hologic). He was also partner at Beringea, leading investments in Life Sciences and Renewables including Biovex (sold for $1bn to Amgen). Stephane turned around and successfully exited a company manufacturing and selling laboratory monitoring equipment. Stephane is a Doctor in Veterinary Medicine, a Veterinary Pathologist and holds an MBA from INSEAD.
Peter Smith, Partner: Peter has significant experience in private equity and corporate finance, previously working with Maven Capital Partners and CPI Enterprises. Peter has led and worked on a number of the most successful transactions during his tenure, including that of Pragmatic (raised over £150m). He has supported a range of fast-growing businesses including Qkine, Q5D, iPac, Descycle. He is responsible for new investments and has overall responsibility for all aspects of the business including strategy, client management and business development. Peter holds an MSc in Finance from Warwick Business School and a first-class degree in Mathematics with Finance from The University of Liverpool.
Green Angel Ventures
Green Angel Ventures is the UK’s reference early stage investor in climate innovation. Since 2017, this specialist climate impact venture capital firm has built an exciting portfolio of ~50 companies fighting climate change in key sectors including energy, transport, circular industry, the built environment and agritech. Green Angel Ventures experienced team manages the EIS Climate Change Fund, benefiting from the expertise of its network of 300+ specialist investors.
Antoine Pradayrol, Chief Investment Officer: Antoine is an experienced climate tech investor, with 25 years' experience in equity investment. Since 2019, he has been leading the development of Green Angel Ventures' fund management activity and he chairs its Investment Committee. Over the last decade, he has built a portfolio of 30 early stage investments and is actively supporting founders as part of the Imperial Venture Mentoring Service; he was formerly on the boards of AirEx and Zedify. Prior to joining Green Angel Ventures, he was a Partner at Exane BNP Paribas.
o2h Ventures
o2h Ventures is a biotech specialist fund manager based in Cambridge, the UK, focused on backing innovative biotech companies that are transforming human health. The company invests in pre-seed and seed-stage ventures developing novel therapeutics, pioneering medical technologies, and software or AI solutions that advance healthcare. o2 Ventures has invested over $10m into more than 35 biotech ventures to date, many of which it has supported from the earliest stages and has since progressed substantially. These companies are tackling areas of high unmet medical need, including cancer, depression, diseases of the ear and eye, psoriasis, idiopathic pulmonary fibrosis, ageing, and infectious diseases. o2 Ventures has invested in spinouts from leading universities such as Cambridge, Oxford, UCL, Dundee, Sussex, and Nottingham—often leading the deals and taking Board positions.
Chris White, Vice President, Business Development: Chris leads fundraising for the o2h human health EIS and SEIS funds, bringing a wealth of experience in business development across the financial services sector. Before joining o2h Ventures, he worked with an independent provider specialising in EIS/SEIS analysis and tax-advantaged investments. His diverse background includes roles in financial media and renewable energy financing. Chris holds a degree in French and European Studies from Aston University.